Antifolates targeted specifically to the folate receptor

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1111-1125

  Jackman, Ann L ^a   Theti, Davinder S ^a   Gibbs, David D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antifolate; Thymidylate synthase; Folate receptor

Indexed keywords

CELLS; CONCENTRATION (PROCESS); DRUG DOSAGE; TISSUE; TOXICITY; TRANSPORT PROPERTIES; TUMORS;

ANTIFOLATE DRUGS; FOLATE RECEPTOR; REDUCED-FOLATE CARRIER (RFC); TRANSPORT MECHANISM;

BIOMEDICAL ENGINEERING;

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 DEAMINO 2 METHYL 10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; CB 300464; CB 300638; CB 300945; CB 30523; CB 30901; CB 3900; CYCLOPENTADIENE DERIVATIVE; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; FOLIC ACID ANTAGONIST; LOMETREXOL; MEMBRANE RECEPTOR; METHOTREXATE; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; PEMETREXED; PLEVITREXED; QUINAZOLINE DERIVATIVE; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; CANCER INHIBITION; CELL GROWTH; DRUG EXPOSURE; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSPORT; EPITHELIUM TUMOR; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; IC 50; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL LINE;

EID: 1942439032     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.003     Document Type: Article

References (72)

1. Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. Folate binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
2. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 73:1994;2432-2443.
3. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L., Old L.J., Retting W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142:1993;557-567.
4. Wu M., Gunning W., Ratnam M. Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8:1999;775-782.
5. Weitman S.D., Lark R.H., Coney L.R., For D.W., Frasca V., Zurawski V.R., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
6. Bueno R., Appasani K., Mercer H., Lester S., Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 121:2001;225-233.
7. Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;293-321 Humana Press Inc. New Jersey.
8. Antony A.C. Folate receptors. Annu. Rev. Nutr. 16:1996;501-521.
9. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes. Correlates of molecular-structure and biological activity. Mol. Pharmacol. 48:1995;459-471.
10. Shih C., Thornton D.E. Preclinical pharmacology studies and the development of the novel multitargeted antifolate, MTA (LY231514). Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;183-201 Humana Press Inc. New Jersey.
11. Kisliuk R.L. Folate biochemistry in relation to antifolate selectivity. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;13-36 Humana Press Inc. New Jersey.
12. Peters G.J., Kolne C.H. Fluoropyrimidines as antifolate drugs. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;101-145 Humana Press Inc. New Jersey.
13. Gorlick R., Bertino J. Clinical pharmacology and resistance to dihydrofolate reductase inhibitors. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;37-57 Humana Press Inc. New Jersey.
14. Jackman A.L., Taylor G.A., Gibson W., Kimbell R., Brown M., Calvert A.H., Judson I.R., Hughes L.R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 51:1991;5579-5586.
15. Jackman A.L., Boyle F.T., Harrap K.R. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Invest. New Drugs. 14:1996;305-316.
16. Beale P., Clarke S. Tomudex: clinical development. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;167-181 Humana Press Inc. New Jersey.
17. Jackman A.L., Kimbell R., Aherne G.W., Brunton L., Jansen G., Stephens T.C., Smith M.N., Wardleworth M.J., Boyle F.T. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, non-polyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res. 3:1997;911-921.
18. Hainsworth J., Vergote I., Janssens J. A review of Phase II studies of ZD9331 treatment for relapsed or refractory solid tumours. Anti-Cancer Drugs. 14:(Suppl. 1):2003;S13-S19.
19. Curtin N.J., Hughes A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2:2001;298-306.
20. Adjei A.A. Pemetrexed (Alimta): a novel multitargeted antifolate agents. Expert Rev. Anticancer Ther. 3:2003;145-156.
21. Vogelzang N.J., Rusthoven J., et al. Phase III single-blinded study of pemetrexed+cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 2002;21.
22. Lancet editorial, Drug company decision to end cancer trial, 354 (1999) p. 1045, 1999.
23. Hoff P.M., Ansari R., Batist G., Cox J., Kocha W., Kuperminc M., Maroun J., Walde D., Weaver C., Harrison E., Burger H.U., Osterwalder B., Wong A.O., Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 19:2001;2282-2292.
24. Van Cutsem E.C., Twelves C., Cassidy J., Allman D., Bajetta E., Boyer M., Bugat R., Findlay M., Frings S., Jahn M., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 19:2001;4097-4106.
25. John W., Picus J., Blanke C.D., Clark J.W., Schulman L.N., Rowinsky E.K., Thornton D.E., Loehrer P.J. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer. 88:2000;1807-1813.
26. Wang X., Shen F., Freisham J.H., Gentry L.E., Ratnam M. Differential sterospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol. 44:1992;1898-1901.
27. Saikawa Y., Knight C.B., Saikawa T., Page S.T., Chabner B.A., Elwood P.C. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J. Biol. Chem. 268:1993;5293-5301.
28. Chung K.N., Saikawa Y., Paik T.H., Dixon K.H., Mulligan T., Cowan K., Elwood P.C. Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. J. Clin. Invest. 91:1993;1289-1294.
29. Dixon K.H., Mulligan T., Chung K.N., Elwood P.C., Cowan K.H. Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-human breast cancer cells. J. Biol. Chem. 267:1992;24140-24147.
30. Westerhof G.R., Rijnboutt S., Schornagel J.H., Pinedo H.M., Peters G.J., Jansen G. Functional activity of the reduced-folate carrier in KB, MA104 and IGROV-1 cells expressing the folate-binding protein. Cancer Res. 55:1995;3795-3802.
31. D.S. Theti, A.L. Jackman, The role of α-folate receptor-mediated transport in the antitumour activity of antifolate drugs, Clin. Cancer Res. (in press).
32. Mendelsohn L.G., Worzalla J.F., Walling J.M. Preclinical and clinical evaluation of the glycinamide ribonucleotide formyltransferase inhibitors lomotrexol and LY309887. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;261-280 Humana Press Inc. New Jersey.
33. Jackman A.L., Calvert A.H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol. 6:1995;871-881.
34. Theti D.S., Bavetsias V., Skelton L.A., Titley J., Gibbs D., Jansen G., Jackman A.L. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumour cell lines overexpressing the α-isoform of the folate receptor. Cancer Res. 63:2003;3612-3618.
35. Clarke S.J., Jackman A.L., Judson I.R. The history of the development and clinical use of CB3717 and ICI D1694. Rustum Y.M. Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. 1993;277-287 Plenum Press, New York.
36. 10-propargyl-5,8- dideazafolic acid. Biochem. Pharmacol. 42:1991;1885-1895.
37. 10-propargyl-5,8-dideazafolic acid (ICI 198583). J. Med. Chem. 39:1996;73-85.
38. Bavetsias V., Marriott J.H., Melin C., Kimbell R., Matusiak Z., Boyle F.T., Jackman A.L. Synthesis of cyclopenta[g]quinazoline-based antifolates, a novel class of thymidylate synthase inhibitors. J. Med. Chem. 43:2000;1910-1926.
39. 10-Propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem. Pharmocol. 37:1988;4047-4054.
40. Boyle F.T., Matusiak Z.S., Hughes L.R., Slater A.M., Stephens T.C., Smith M.N., Kimbell R., Jackman R.A.L. Substituted-2-desamino-2-methyl- quinazolinones. A series of novel antitumour agents. Adv. Exp. Med. Biol. vol. 338:1993;585-588 Plenum Press.
41. Jackman A.L., Kimbell R., Brown M., Brunton L., Boyle F.T. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Anti-Cancer Drug Des. 10:1995;555-572.
42. Sanghani P.C., Jackman A.L., Evans V.R., Thornton T., Hughes L., Calvert A.H., Moran R.G. A strategy for the design of membrane-permeable folylpolyglutamate synthetase inhibitors: "bay region" -substituted 2-desamino-2-methyl-5,8-dideazafolate analogues. Mol. Pharmacol. 45:1994;341-351.
43. Marriott J.H., Neidle S., Matusiak Z., Bavetsias V., Jackman A.L., Melin C., Boyle F.T. Chemoenzymatic preparation of the novel antifolate thymidylate synthase inhibitor N-{4-[N-((6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-prop-2-ynyl)amino]benzoyl}-L-glutamic acid and its glutamyl cleavage product. J. Chem. Soc. Perkin Trans. 1:1999;1495-1503.
44. Jansen G., Kathman I., Rademaker B.C., Braakhuis B.J.M., Westerhof G.R., Rijksen G., Schornagel J.H. Expression of folate binding protein in L1210 cells grown in low folate medium. Cancer Res. 49:1989;1959-1963.
45. Gibbs D., Carnochan P., Raynaud F., Valenti M., Jackman A.L. CB300638, an α-FR targeted antifolate thymidylate synthase (TS) inhibitor that inhibits TS in human tumour xenografts but not in normal tissues. Proc. Am. Assoc. Cancer Res. 44:2003;599.
46. Jackman A.L., Gibbs D., Theti D., Green M., Raynaud F., Valenti M., Bavetsias V. The development of α-folate receptor targeted thymidylate synthase inhibitors. Br. J. Cancer. 88:2003;S21.
47. 125I] iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors. Eur. J. Cancer. 32A:1996;1603-1608.
48. Dupertuis Y.M., Vazquez M., Mach J.P., De Tribolet N., Pichard C., Slosman D.O., Buchegger F. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabelled iododeoxyuridine. Cancer Res. 61:2001;7971-7977.
49. Benepal T., Mitchell F., Gibbens I., Gore M., Jackman A.L. Estimation of plasma thymidine in healthy volunteers vs. cancer patients by high performance liquid chromatography. Br. J. Cancer. 88:2003;S56.
50. Jackman A.L., Taylor G.A., Calvert A.H., Harrap K.R. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717. Biochem. Pharmacol. 33:1984;3269-3275.
51. Hughes L.R., Stephens T.C., Boyle F.T., Jackman A.L. Raltitexed (Tomudex™), a highly polyglutamated antifolate thymidylate synthase inhibitor. Design and pre-clinical activity. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;243-260 Humana Press Inc. New Jersey.
52. Boyle F.T., Stephens T.C., Averbuch S.D., Jackman A.L. ZD9331, preclinical and clinical studies. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;37-57 Humana Press Inc. New Jersey.
53. Smith G.K., Bigley J.W., Dev I.K., Duch R., Pendergast W. GW1843: a potent, non-competitive thymidylate synthase inhibitor - preclinical and preliminary clinical studies. Jackman A.L. Antifolate Drugs in Cancer Chemotherapy. 1999;203-227 Humana Press Inc. New Jersey.
54. Cao S., McGuire J.J., Rustum Y.M. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Clin. Cancer Res. 5:1999;1925-1934.
55. Morshed K.M., Ross D.M., McMartin K.E. Folate transport proteins mediate the bi-directional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells. J. Nutr. 127:1997;1137-1147.
56. Selhub J., Franklin W.A. The folate binding protein of rat kidney. Purification, properties and cellular distribution. J. Biol. Chem. 259:1984;6601-6606.
57. Jodrell D.I., Newell D.R., Morgan S.E., Clinton S., Bensted J.P., Hughes L., Calvert A.H. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694 in mice. Br. J. Cancer. 64:1991;833-838.
58. Walton M.I., Mitchell F., Aherne G.W., Medlow C.J., Boyle F.T., Jackman A.L. The renal effects of the water-soluble, non-folylpolyglutamate synthetase dependent thymidylate synthase inhibitor ZD9331 in mice. Br. J. Cancer. 78:1998;1457-1463.
59. Dejonge M.J., Punt C.J., Sparreboom A., Planting A.S., Peters M.E., Van De Schraaf J., Jackman A., Smith R., Mulder P.H., Verweij J. Phase I and pharmacologic study of oral ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J. Clin. Oncol. 20:2002;1923-1931.
60. Goh B.C., Ratain M.J., Bertucci D., Smith R., Mani S., Vogelzang N.J., Schilsky R.L., Hutchison M., Smith M., Averbuch S., Douglass E. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J. Clin. Oncol. 19:2001;1476-1484.
61. Aherne G.W., Ward E., Lawrence N., Dobinson D., Clarke S.J., Musgrove H., Sutcliffe F., Stephens T., Jackman A.L. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor in preclinical models. Br. J. Cancer. 77:1998;221-226.
62. Aherne G.W., Hardcastle A., Ward E., Dobinson D., Crompton T., Valenti M., Brunton L., Jackman A.L. Pharmacokinetic/pharmacodynamic study of ZD9331, a non-polyglutamatable inhibitor of thymidylate synthase in a murine model following two curative administration schedules. Clin. Cancer Res. 7:2001;2923-2930.
63. Plummer R., Rees C., Hughes A., Beale P., Highley M., Trigo J., Gokul S., Judson I., Calvert H., Jackman A., Mitchell F., Smith R., Douglass E. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. Clin. Cancer Res. 9:2003;1313-1322.
64. Ford H.E., Mitchell F., Cunningham D., Farrugia D.C., Hill M.E., Rees C., Calvert A.H., Judson I.R., Jackman A.L. Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin. Cancer Res. 8:2002;103-109.
65. Welsh S.J., Titley J., Brunton L., Valenti M., Monaghan P., Jackman A.L., Aherne G.W. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumour cell lines and tissues. Clin. Cancer Res. 6:2000;2538-2546.
66. Shields A.F., Grierson J.R., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4:1998;1334-1336.
67. Carnochan P., Brooks R. Radiolabelled 5′-iodo-2′- deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment. Nucl. Med. Biol. 26:1999;667-672.
68. 124I]iododeoxyuridine. Cancer Res. 60:2000;624-635.
69. Mantovani L.T., Miotti S., et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur. J. Cancer. 30A:1994;363-369.
70. Bagnoli M., Tomassetti A., Figini M., Flati S., Dolo V., Canevari S., Miotti S. Down modulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression. Oncogene. 19:2000;4754-4763.
71. Westerhof G.R., Jansen G., Emmerik N., Kathman I., Rijksen G., Jackman A.L., Schornagel J.H. Membrane transport of natural and antifolate compounds in murine L1210 leukaemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res. 51:1991;5507-5513.
72. Jackman A.L., Kimbell R., Brown M., Brunton L., Bisset G.M.F., Bavetsias V., Marsham P., Hughes L.R., Boyle F.T. Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation. Anti-Cancer Drug Des. 10:1995;573-589.